Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
LH 
Laboratory Corporation of America Holdings (LH)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/27/2025: LH (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Analysis of Past Performance
Type Stock | Historic Profit 2.26% | Avg. Invested days 48 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 03/27/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 19.48B USD | Price to earnings Ratio 26.33 | 1Y Target Price 273.6 |
Price to earnings Ratio 26.33 | 1Y Target Price 273.6 | ||
Volume (30-day avg) 625176 | Beta 1.11 | 52 Weeks Range 190.25 - 258.59 | Updated Date 04/1/2025 |
52 Weeks Range 190.25 - 258.59 | Updated Date 04/1/2025 | ||
Dividends yield (FY) 1.24% | Basic EPS (TTM) 8.84 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 5.74% | Operating Margin (TTM) 6.93% |
Management Effectiveness
Return on Assets (TTM) 4.05% | Return on Equity (TTM) 9.36% |
Valuation
Trailing PE 26.33 | Forward PE 14.56 | Enterprise Value 25234438000 | Price to Sales(TTM) 1.5 |
Enterprise Value 25234438000 | Price to Sales(TTM) 1.5 | ||
Enterprise Value to Revenue 1.94 | Enterprise Value to EBITDA 13.93 | Shares Outstanding 83700000 | Shares Floating 83316654 |
Shares Outstanding 83700000 | Shares Floating 83316654 | ||
Percent Insiders 0.34 | Percent Institutions 96.06 |
Analyst Ratings
Rating 4.26 | Target Price 261.36 | Buy 2 | Strong Buy 11 |
Buy 2 | Strong Buy 11 | ||
Hold 6 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Laboratory Corporation of America Holdings
Company Overview
History and Background
Laboratory Corporation of America Holdings (Labcorp) was founded in 1978 as Roche Biomedical Laboratories. It underwent several acquisitions and name changes, becoming Labcorp in 1995. It has grown through strategic acquisitions and organic growth, becoming a leading global life sciences company.
Core Business Areas
- Diagnostics: Clinical laboratory testing services, including routine blood tests, specialized diagnostics, and genomic testing. It is Labcorp's largest business segment.
- Drug Development: Provides contract research services for pharmaceutical and biotechnology companies, including preclinical and clinical trial support.
Leadership and Structure
Adam H. Schechter serves as the Chairman and CEO. The organizational structure includes various business units and functional departments (e.g., Diagnostics, Drug Development, Finance, Operations) reporting to the CEO.
Top Products and Market Share
Key Offerings
- COVID-19 Testing: Labcorp was a major provider of COVID-19 tests. It held significant market share during the pandemic peak but has declined since. Competitors include Quest Diagnostics, independent labs, and hospital labs. Revenue contributed significantly to the overall revenue the last 2 years and market share data may change.
- Oncology Testing: A wide range of diagnostic tests for cancer detection, monitoring, and treatment selection. Competitors include NeoGenomics, Exact Sciences, and specialized hospital labs. Labcorp is a leader in this space.
- Routine Blood Tests: Standard blood tests for various health conditions. Competitors include Quest Diagnostics, independent labs, and hospital labs. The market share is well split up amoung a number of participants
- Esoteric Testing: Specialized and less common diagnostic tests for rare or complex conditions, representing a higher margin business.
Market Dynamics
Industry Overview
The clinical laboratory testing industry is characterized by increasing demand for diagnostic services, technological advancements, and evolving regulatory landscapes. The industry is also experiencing consolidation, with larger players acquiring smaller labs. Personalized medicine and the need for specialized testing continue to drive growth.
Positioning
Labcorp is one of the two largest clinical laboratory companies in the US, along with Quest Diagnostics. Its competitive advantages include its scale, extensive test menu, national network of laboratories, and strong relationships with healthcare providers. It is also expanding into personalized medicine and digital health.
Total Addressable Market (TAM)
The global clinical laboratory services market is estimated to be worth hundreds of billions of dollars annually. Labcorp is well-positioned to capture a significant share of this market through its diverse service offerings and extensive network.
Upturn SWOT Analysis
Strengths
- Large scale and national network
- Comprehensive test menu
- Strong relationships with healthcare providers
- Brand recognition
- Established infrastructure for drug development services
Weaknesses
- Dependence on reimbursement rates
- Exposure to regulatory changes
- Competition from hospitals and smaller labs
- Potential for data breaches
- Price competition
Opportunities
- Expanding into emerging markets
- Developing new diagnostic tests
- Partnering with pharmaceutical companies for drug development
- Leveraging digital health technologies
- Growing demand for personalized medicine
- Aging population
Threats
- Decreasing reimbursement rates
- Increased competition
- Technological obsolescence
- Economic downturns
- Regulatory changes
Competitors and Market Share
Key Competitors
- QDEL
- DGX
- LH
Competitive Landscape
Labcorp and Quest Diagnostics dominate the market. Other competitors include regional labs and specialty testing companies. Labcorp's advantages include its scale, comprehensive test menu, and established relationships. Disadvantages are price and regional limitations.
Major Acquisitions
Personal Genome Diagnostics Inc.
- Year: 2022
- Acquisition Price (USD millions): 450
- Strategic Rationale: Expanded Labcorp's oncology testing capabilities.
Growth Trajectory and Initiatives
Historical Growth: Historically, Labcorp has grown through acquisitions and organic expansion. Recent years have seen significant revenue increases driven by COVID-19 testing, followed by stabilization.
Future Projections: Analyst estimates depend on market conditions and Labcorp's strategic initiatives. Consensus estimates are available from financial data providers.
Recent Initiatives: Focus on strategic acquisitions, expansion of specialized testing services, and investments in technology to improve efficiency and customer experience.
Summary
Labcorp is a leading clinical laboratory company with a wide range of services and a strong market position. It has benefited from COVID-19 testing, but now focuses on strategic acquisitions and growth in specialized testing areas. The company is exposed to reimbursement pressures and regulatory changes. But it is poised to drive future growth through technology advancements.
Similar Companies
- DGX
- HOLX
- BIO
- IQV
- CRL
Sources and Disclaimers
Data Sources:
- Labcorp Investor Relations
- SEC Filings
- Industry Reports
- Financial Data Providers
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Market conditions and company performance can change. Consult with a qualified financial advisor before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Laboratory Corporation of America Holdings
Exchange NYSE | Headquaters Burlington, NC, United States | ||
IPO Launch date 1990-03-29 | President, CEO & Chairman Mr. Adam H. Schechter | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 60900 | Website https://www.labcorp.com |
Full time employees 60900 | Website https://www.labcorp.com | ||
Labcorp Holdings Inc. provides laboratory services. It operates through two segments, Diagnostics Laboratories and Biopharma Laboratory Services. The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid, PAP, hemoglobin A1C, prostate-specific antigens, sexually transmitted diseases, hepatitis C, vitamin D, microbiology cultures and procedures, and alcohol and other substance-abuse tests. It also provides specialty testing services comprising gene-based and esoteric testing; advanced tests target specific diseases; services related to anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, parentage and donor testing, occupational testing services, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests; and health and wellness services to employers and managed care organizations (MCOs). In addition, the company offers online and mobile applications that enable patients to check offerings, schedule PSC visits, check-in upon PSC arrival, complete documentation, access tests and test results, and manage their accounts; online applications for providers, MCOs, and accountable care organizations; specimen collection services; and drug development, medical device, and companion diagnostic development solutions, as well as support for crop protection and chemical testing. It serves pharmaceutical, biotechnology, medical device, and diagnostics companies; and MCOs, employer plans, other health insurance providers, governments, physician, large provider organizations, other healthcare providers, hospitals and health systems, patients and consumers, crop protection and chemical companies, academic institutions, independent clinical laboratories, and retailers. The company was founded in 1995 is headquartered in Burlington, North Carolina.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.